VBIV News and Press, VBI Vaccines Inc.

Among the 7 patients on VBI-1901 treatment long enough to have 1+ MRI scan at the time of analysis, one partial tumor response (PR) and two stable disease (SD) observations have occurred as of May 15, 2024 The partial response, which demonstrated a 67% reduction in tumor size vs. baseline, wa...

VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that new interim tumor response data from the ongoing randomized, controlled Phase 2b study of VBI-1901, the Company’s ca...

2024-05-15 17:06:10 ET More on VBI Vaccines VBI Vaccines expands collaboration with Canadian government Seeking Alpha’s Quant Rating on VBI Vaccines Historical earnings data for VBI Vaccines Financial information for VBI Vaccines Read the ful...

PreHevbrio ® (Hepatitis B Vaccine [Recombinant]) global net revenue increased 105% year-over-year in the first quarter of 2024 compared to the first quarter of 2023 Initial encouraging tumor response data from randomized Phase 2b study of VBI-1901 in recurrent glioblastoma (GBM) anno...

2024-04-16 13:52:44 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips VBI Vaccines (NASDAQ: VBIV ) just reported results for the fourth quarter of 2023. VBI Vaccines reported earnings per share of -1 cent. This was above the analyst estimate...

2024-04-16 11:53:05 ET More on VBI Vaccines VBI Vaccines expands collaboration with Canadian government VBI signs deal to sell manufacturing capabilities, certain assets with Brii Biosciences Seeking Alpha’s Quant Rating on VBI Vaccines Historical earn...

PreHevbrio ® (Hepatitis B Vaccine [Recombinant]) global net revenue increased 234% year-over-year from 2022 to 2023 Preliminary 2024 PreHevbrio U.S. sales demonstrate continued growth, with approximately 65% of 2023 full-year volume sold in Q1 2024 alone Early data from randomize...

VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced the closing of its previously announced registered direct offering priced at-the-market under Nasdaq rules of 2,272,728 of its c...

A look at the top 10 most actives in the United States Selina Hospitality PLC (SLNA) rose 96.2% to $0.0785 on volume of 428,216,483 shares Mobile Global Esports Inc. (MGAM) rose 77.8% to $0.216 on volume of 139,335,972 shares PROSHARES TRUST (SQQQ) fell 1.2% to $10.61 on volume of 128,866...

VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that it has entered into definitive agreements for the sale and issuance of 2,272,728 common shares (or pre-funded warrants in l...